ADB-BUTINACA (also known as ADMB-BINACA using EMCDDA naming standards) is a synthetic cannabinoid compound which has been sold as a designer drug. It is a potent CB<sub>1</sub> agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC<sub>50</sub> of 6.36 nM for CB1.